Technical Analysis for FNCH - Finch Therapeutics Group, Inc.

Grade Last Price % Change Price Change
F 15.99 -2.97% -0.49
FNCH closed down 2.97 percent on Friday, April 16, 2021, on 25 percent of normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A N/A Down
Historical FNCH trend table...

Date Alert Name Type % Chg
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Down 5 Days in a Row Weakness 0.00%
Narrow Range Bar Range Contraction -2.97%
Down 3 Days in a Row Weakness -2.97%
Down 4 Days in a Row Weakness -2.97%
Down 5 Days in a Row Weakness -2.97%
Hot IPO Pullback Bullish Swing Setup -4.02%
Inside Day Range Contraction -4.02%
Down 3 Days in a Row Weakness -4.02%
Older End-of-Day Signals for FNCH ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 5% 1 day ago
Down 3% 1 day ago
Down 2 % 1 day ago
Fell Below Previous Day's Low 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Finch Therapeutics Group, Inc. Description

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company's lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn's disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Biopharmaceutical Clinical Medicine Autoimmune Diseases Infection Specialty Drugs Colitis Ulcerative Colitis Diarrhea Abdominal Pain Crohn's Disease Chronic Hepatitis B Virus Clostridioides Difficile Autism Spectrum Disorder University Of Minnesota

Is FNCH a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 22.5
52 Week Low 15.265
Average Volume 225,760
200-Day Moving Average 0.00
50-Day Moving Average 0.00
20-Day Moving Average 16.77
10-Day Moving Average 16.72
Average True Range 1.46
ADX 0.0
+DI 12.58
-DI 15.23
Chandelier Exit (Long, 3 ATRs ) 18.12
Chandelier Exit (Short, 3 ATRs ) 19.64
Upper Bollinger Band 19.42
Lower Bollinger Band 14.13
Percent B (%b) 0.35
BandWidth 31.55
MACD Line -0.06
MACD Signal Line 0.03
MACD Histogram -0.0936
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.48
Resistance 3 (R3) 17.53 17.08 17.23
Resistance 2 (R2) 17.08 16.70 17.06 17.15
Resistance 1 (R1) 16.54 16.47 16.31 16.49 17.07
Pivot Point 16.09 16.09 15.98 16.06 16.09
Support 1 (S1) 15.54 15.71 15.32 15.49 14.91
Support 2 (S2) 15.09 15.47 15.07 14.83
Support 3 (S3) 14.55 15.09 14.75
Support 4 (S4) 14.50